Artemether-lumefantrine Treatment Failure Despite Adequate Lumefantrine Day 7 Concentration in a Traveller With Plasmodium Falciparum Malaria After Returning From Tanzania

Malar J. 2012 May 25;11:176. doi: 10.1186/1475-2875-11-176.

Abstract

Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa. Genotyping confirmed recrudescence and suggested reduced sensitivity. Potential sub-optimal effect of artemether-lumefantrine highlights the need to follow non-immune individuals the weeks after treatment.

Publication types

  • Case Reports

MeSH terms

  • Antimalarials / administration & dosage*
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins / administration & dosage*
  • Drug Combinations
  • Drug Resistance
  • Ethanolamines / administration & dosage*
  • Fluorenes / administration & dosage*
  • Genotype
  • Humans
  • Malaria, Falciparum / drug therapy*
  • Male
  • Middle Aged
  • Plasmodium falciparum / classification
  • Plasmodium falciparum / drug effects
  • Plasmodium falciparum / genetics
  • Plasmodium falciparum / isolation & purification
  • Recurrence
  • Tanzania
  • Travel*
  • Treatment Failure

Substances

  • Antimalarials
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins
  • Drug Combinations
  • Ethanolamines
  • Fluorenes